CO5390073A1 - Forma de dosificacion oral solida de simeticona - Google Patents

Forma de dosificacion oral solida de simeticona

Info

Publication number
CO5390073A1
CO5390073A1 CO02087102A CO02087102A CO5390073A1 CO 5390073 A1 CO5390073 A1 CO 5390073A1 CO 02087102 A CO02087102 A CO 02087102A CO 02087102 A CO02087102 A CO 02087102A CO 5390073 A1 CO5390073 A1 CO 5390073A1
Authority
CO
Colombia
Prior art keywords
dosage form
simethicone
adsorbent
simeticone
oral dosage
Prior art date
Application number
CO02087102A
Other languages
English (en)
Inventor
Szymczack Chritopher
James T Walter
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Publication of CO5390073A1 publication Critical patent/CO5390073A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee una composición para producir una forma de dosificación sólida comprimida que es una mezcla comprimible de flujo libre de simeticona y adsorbente, y un agente activo opcional, en la cual la relación en peso de simeticona a adsorbente es al menos 1:2.22; asimismo se incluyen formas de dosificación sólidas elaboradas a partir de una mezcla comprimible de flujo libre de simeticona, un adsorbente y un agente activo opcional, en la cual la relación en peso de simeticona a adsorbente es al menos 1:2.22.
CO02087102A 2001-09-28 2002-09-27 Forma de dosificacion oral solida de simeticona CO5390073A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/966,441 US7101573B2 (en) 2001-09-28 2001-09-28 Simethicone solid oral dosage form

Publications (1)

Publication Number Publication Date
CO5390073A1 true CO5390073A1 (es) 2004-04-30

Family

ID=25511414

Family Applications (1)

Application Number Title Priority Date Filing Date
CO02087102A CO5390073A1 (es) 2001-09-28 2002-09-27 Forma de dosificacion oral solida de simeticona

Country Status (18)

Country Link
US (3) US7101573B2 (es)
EP (1) EP1297825B1 (es)
AR (1) AR036700A1 (es)
AT (1) ATE296619T1 (es)
AU (1) AU2002301259C1 (es)
BR (1) BR0204001A (es)
CA (1) CA2405190C (es)
CO (1) CO5390073A1 (es)
DE (1) DE60204403T2 (es)
DK (1) DK1297825T3 (es)
ES (1) ES2243664T3 (es)
HU (1) HUP0203176A2 (es)
MX (1) MXPA02009570A (es)
NZ (1) NZ521657A (es)
PL (1) PL204141B1 (es)
PT (1) PT1297825E (es)
RU (1) RU2362569C2 (es)
ZA (1) ZA200207755B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
EP1509204A4 (en) * 2001-11-29 2005-07-13 Rettenmaier & Soehne Gmbh & Co AGGLOMERATED PARTICLES WITH AN ACTIVE SUBSTANCE PREPARED WITH MELTED MICROCRYSTALLINE CELLULOSE
US7179488B2 (en) 2001-11-29 2007-02-20 Bob Sherwood Process for co-spray drying liquid herbal extracts with dry silicified MCC
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition
US7341742B2 (en) * 2002-09-30 2008-03-11 L. Perrigo Company Simethicone containing tablet composition and method
EP1563837A1 (en) * 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
JP2008503445A (ja) * 2004-04-13 2008-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 便秘患者におけるシメチコンの使用
CA2565941A1 (en) * 2004-05-04 2005-11-10 Equitech Corporation Improved nsaid composition
US20060024409A1 (en) * 2004-07-29 2006-02-02 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
US20060024384A1 (en) * 2004-07-29 2006-02-02 Giordano John A Compositions and methods for nutrition supplementation
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
BRPI0608928A2 (pt) * 2005-03-24 2010-02-17 Daiichi Sankyo Co Ltd composição farmacêutica
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
BRPI0615607A2 (pt) * 2005-08-30 2011-05-24 Lek Pharmaceuticals composição farmacêutica compreendendo perindopril ou seus sais
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
US20080015260A1 (en) * 2006-07-13 2008-01-17 Kiel Laboratories, Inc. Pharmaceutical compositions having improved stability and methods for preparation and use
US20080038410A1 (en) * 2006-08-18 2008-02-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
WO2008056200A1 (en) * 2006-11-10 2008-05-15 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of simethicone
ES2494848T3 (es) 2006-11-21 2014-09-16 Mcneil-Ppc, Inc. Suspensiones analgésicas de liberación modificada
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
WO2009105568A1 (en) 2008-02-20 2009-08-27 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
EP2373791B1 (en) 2009-01-06 2016-03-30 Curelon LLC Compositions comprising protease, amylase and lipase for use in the treatment of staphylococcus aureus infections
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
JP5410819B2 (ja) * 2009-04-09 2014-02-05 ライオン株式会社 木クレオソート含有固形製剤
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
JP2014516080A (ja) 2011-06-08 2014-07-07 エスティーアイ ファーマ， エルエルシー 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤
RU2617510C2 (ru) 2011-09-08 2017-04-25 Новартис Аг Фармацевтические композиции, содержащие ингибитор ароматазы
BR112014009946A2 (pt) * 2011-10-27 2017-04-25 Salix Pharmaceuticals Inc "composição, composição farmacêutica ou formulação purgativas e uso das mesmas"
ITMI20112221A1 (it) * 2011-12-05 2013-06-06 Altergon Sa Formulazioni stabili in capsule di gelatina molle di antiaggreganti piastrinici, acidi grassi omega-3 e amilosio
EP2790676B1 (en) 2011-12-14 2018-01-10 Disphar International B.V. Simethicone formulation
RU2491941C1 (ru) * 2011-12-27 2013-09-10 Вадим Алексеевич Козловский Композиционный энтеросорбент
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
MA41620A (fr) 2015-05-14 2018-01-09 Abdi Ibrahim Ilac Sanayi Ve Ticaret A S Composition pharmaceutique comprenant de la siméthicone et de l'otilonium
JP6724537B2 (ja) * 2015-05-26 2020-07-15 大正製薬株式会社 固形製剤
WO2016201119A1 (en) * 2015-06-09 2016-12-15 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
US10166185B2 (en) * 2015-06-09 2019-01-01 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
WO2016200345A1 (en) 2015-06-12 2016-12-15 Santa Farma İlaç Sanayi̇ A. Ş. Oral pharmaceutical composition comprising otilonium bromide and simethicone with certain bulk density and improved dissolution characteristics.
EP3364955B1 (en) 2015-10-09 2022-04-20 RB Health (US) LLC Pharmaceutical formulation
MX2016016587A (es) * 2016-12-14 2018-06-13 Rhein Siegfried Sa De Cv Composicion mejorada de lansoprazol y simeticona y procesos para prepararla.
KR102648960B1 (ko) 2017-09-29 2024-03-20 존슨 앤드 존슨 컨수머 인코포레이티드 고체 시메티콘 입자 및 이의 투여 형태
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
FR3117780B1 (fr) * 2020-12-22 2024-04-05 Oreal Composition anhydre sous forme de poudre compacte comprenant un sel de magnesium et de la cellulose microcristalline

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56169622A (en) * 1980-06-03 1981-12-26 Kissei Pharmaceut Co Ltd Method of making solid preparation from oily substance
US4744987A (en) * 1985-03-08 1988-05-17 Fmc Corporation Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
US4851226A (en) * 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US4906478A (en) * 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US5073384A (en) * 1989-10-19 1991-12-17 Valentine Enterprises, Inc. Maltodextrin/defoaming composition combinate
US5275822A (en) * 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
IN171919B (es) * 1989-11-01 1993-02-06 Mcneil Ppc Inc
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
JP3177707B2 (ja) 1991-10-08 2001-06-18 堀井薬品工業株式会社 消化管内ガス除去剤
NZ252433A (en) * 1992-04-30 1996-07-26 Schering Corp Preparation of a dry hydrated cephalosporin powder formulation which is resistant to air oxidation and dehydration by mixing the drug with dry excipients and filling into a sealable storage container
GR1002332B (el) * 1992-05-21 1996-05-16 Mcneil-Ppc Inc. Νεες φαρμακευτικες συνθεσεις που περιεχουν σιμεθεικονη.
CA2110313C (en) * 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
FR2705966B1 (fr) * 1993-06-04 1995-08-25 Dow Corning Sa Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
JPH09504293A (ja) * 1993-10-28 1997-04-28 ザ、プロクター、エンド、ギャンブル、カンパニー マグネシウムアルミニウムシリケート及び複数の活性成分を含有した速溶解性剤形
EP0659403B1 (en) 1993-12-15 2001-03-14 National Starch and Chemical Investment Holding Corporation Use of oil adsorbent natural polymer for cosmetic and pharmaceutical applications
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications
US6126967A (en) 1998-09-03 2000-10-03 Ascent Pediatrics Extended release acetaminophen particles
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form

Also Published As

Publication number Publication date
US7691409B2 (en) 2010-04-06
DE60204403T2 (de) 2006-05-04
NZ521657A (en) 2004-05-28
MXPA02009570A (es) 2004-07-30
HUP0203176A2 (hu) 2004-07-28
RU2002125821A (ru) 2004-03-27
US20030091624A1 (en) 2003-05-15
AU2002301259C1 (en) 2009-07-23
CA2405190C (en) 2010-11-09
US7101573B2 (en) 2006-09-05
ATE296619T1 (de) 2005-06-15
DK1297825T3 (da) 2005-09-26
PL204141B1 (pl) 2009-12-31
PT1297825E (pt) 2005-08-31
AU2002301259B2 (en) 2009-01-22
EP1297825B1 (en) 2005-06-01
RU2362569C2 (ru) 2009-07-27
PL356358A1 (en) 2003-04-07
AR036700A1 (es) 2004-09-29
US20100135982A1 (en) 2010-06-03
ES2243664T3 (es) 2005-12-01
ZA200207755B (en) 2004-03-26
US20070196468A1 (en) 2007-08-23
DE60204403D1 (de) 2005-07-07
CA2405190A1 (en) 2003-03-28
HU0203176D0 (es) 2002-11-28
EP1297825A1 (en) 2003-04-02
BR0204001A (pt) 2003-09-16

Similar Documents

Publication Publication Date Title
CO5390073A1 (es) Forma de dosificacion oral solida de simeticona
BR0311867A (pt) Forma de ministração adesiva a mucosa em forma de pelìcula e uso de um extrato ou de um óleo de cannabis para a produção de uma forma de ministração adesiva a mucosa em forma de pelìcula
CY1118211T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν ενωσεις λανθανιου
BRPI0519212A2 (pt) composiÇÕes farmacÊuticas de desintegraÇço oral contendo agentes de manifestaÇço sensorial
GT200600023A (es) Combinacion de xolair con agente inmunosupresivo
BR0215193A (pt) Formulações de azitromicina diretamente compressìveis
CL2008002407A1 (es) Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04).
CL2004002017A1 (es) Forma de dosificacion termoformada a prueba de abuso que contiene (a) uno o mas principios activos susceptibles de abuso, (b) opcionalmente sustancias auxiliares, (c) al menos un polimero sintetico o natural de un grupo definido y (d) opcionalmente a
PT1401501E (pt) Composicoes farmaceuticas orais com libertacao modificada do ingrediente activo
ES2182357T3 (es) Nueva utilizacion de budesonide y formoterol.
DE60125825D1 (de) Parfümzusammensetzungen
CO5210903A1 (es) Composiciones novedosas de mezcla de aceite
EA200701107A1 (ru) Твердая фармацевтическая композиция, содержащая валсартан
MXPA06010767A (es) Composicion farmaceutica anhidra que asocia un agente siliconado y principio activo solubilizado.
SG158869A1 (en) A tetracycline metal complex in a solid dosage form
UY27296A1 (es) Composición farmacéutica que contiene mosaprida y pancreatina
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
BR0311663A (pt) Preparação em forma de pelìcula contendo uma substância ativa, uso de uma preparação e processo para a produção de uma preparação
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
BR0202491A (pt) Forma de dosagem de núcleo macio, de revestimento frágil
AR036085A1 (es) Formas de dosificacion y procedimiento para su fabricacion
BR0314787A (pt) Forma de dosagem de liberação modificada
EP1570842A3 (en) Composition containing chondroitin sulphate
RU2002105454A (ru) Косметическая маска для лица

Legal Events

Date Code Title Description
FC Application refused